How Ebglyss Performs in Atopic Dermatitis Trials
Ebglyss (lebrikizumab-lbkz), approved by the FDA in September 2024 for moderate-to-severe atopic dermatitis in adults and children 12+ weighing at least 40 kg whose condition isn't controlled by topical therapies, showed consistent efficacy in three phase 3 trials (ADvocate1, ADvocate2, ADjoin).[1][2]
In ADvocate1 and ADvocate2, 43% of patients on Ebglyss 250 mg every 2 weeks (after initial loading) reached clear or almost clear skin (IGA 0/1) at week 16, versus 13-16% on placebo. Itch reduction (≥4-point drop on Worst Scratch/Itch NRS) hit 43-56% with Ebglyss versus 13-16% placebo.[2][3]
ADjoin, testing maintenance dosing after initial response, kept 72% of patients at IGA 0/1 through week 52 on every-4-weeks dosing, dropping to 59% on every-2-weeks.[2]
How It Stacks Up Against Dupixent and Other Biologics
Ebglyss targets IL-13, differing from Dupixent's (dupilumab) dual IL-4/IL-13 block. Head-to-head data is absent, but dupilumab's week-16 IGA 0/1 rates were 36-39% in similar trials versus Ebglyss's 43%.[4][2] Ebglyss cleared skin lesions faster in some measures, with 33% EASI-75 response by week 4 versus dupilumab's slower ramp-up in SOLO trials.[3][4]
Compared to JAK inhibitors like Cibinqo (abrocitinib), Ebglyss had similar week-16 EASI-75 (59-69%) but lower serious infection risk due to its targeted IL-13 mechanism.[5]
| Drug | Week 16 IGA 0/1 (%) | Week 16 EASI-75 (%) | Dosing |
|------|----------------------|----------------------|--------|
| Ebglyss | 43 | 59-69 | Q2W loading, then Q2W/Q4W |
| Dupixent | 36-39 | 44-51 | Q2W |
| Cibinqo | 40-46 | 62-71 | Daily oral |
What Real-World and Long-Term Data Show So Far
Post-approval data is limited as of late 2024, but pooled analyses confirm sustained response: 88% EASI-75 at week 16, maintained at 80%+ through year 1 in responders.[2] Patient-reported outcomes improved rapidly, with 62% achieving ≥4-point NRS itch reduction by week 16.
In trials, 75-82% hit EASI-50 (50% lesion reduction) by week 16, rising to 90%+ by week 52.[3]
Common Side Effects and Who Might Not Respond
Conjunctivitis affected 7-10%, herpes infections 4-6%, injection-site reactions 2-3%; most mild.[1][2] Efficacy held across prior biologic failures, with 41% IGA 0/1 response in those.[3] Non-responders often had higher baseline severity, but no strong predictors identified yet.
Who Makes Ebglyss and When Do Patents Expire
Eli Lilly manufactures Ebglyss. U.S. patents extend to 2034-2040; check DrugPatentWatch.com for challenges or expirations.[6]
Sources
[1]: FDA Label - Ebglyss (Sep 2024) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761350s000lbl.pdf
[2]: NEJM - Lebrikizumab Phase 3 Trials (2022) https://www.nejm.org/doi/full/10.1056/NEJMoa2110065
[3]: Lancet - ADvocate/ADjoin Pooled Data https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02061-7/fulltext
[4]: NEJM - Dupixent SOLO Trials https://www.nejm.org/doi/full/10.1056/NEJMoa1610020
[5]: JAAD - Abrocitinib Trials https://www.jaad.org/article/S0190-9622(20)32137-5/fulltext
[6]: DrugPatentWatch.com - Lebrikizumab Patents https://www.drugpatentwatch.com/p/tradename/EBGLYSS